Program Committee Disclosures

AAO 2024 /

Program /

CME Information /

Program Committee Disclosures

Program Committee Disclosures

The Academy has a profound duty to its members, the larger medical community and the public to ensure the integrity of all of its scientific, educational, advocacy and consumer information activities and materials. Thus each Academy Trustee, Secretary, committee Chair, committee member, taskforce chair, taskforce member, councilor, and representative to other organizations (“Academy Leader”), as well as the Academy staff and those responsible for organizing and presenting CME activities must disclose interactions with Companies and manage conflicts of interest or the appearance of conflicts of interest that affect this integrity. Where such conflicts or perceived conflicts exist, they must be appropriately and fully disclosed and mitigated.

All contributors to Academy educational and leadership activities must disclose all financial relationships (defined below) to the Academy annually. The ACCME requires the Academy to disclose the following to participants prior to the activity:

All financial relationships with Commercial Companies that contributors have had within the previous 24 months. A commercial company is any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients.
Meeting presenters, authors, contributors or reviewers who report they have no known financial relationships to disclose.

The Academy will request disclosure information from meeting presenters, authors, contributors or reviewers, committee members, Board of Trustees, and others involved in Academy leadership activities (“Contributors”) annually. Disclosure information will be kept on file and used during the calendar year in which it was collected for all Academy activities. Updates to the disclosure information file should be made whenever there is a change. At the time of submission of a Journal article or materials for an educational activity or nomination to a leadership position, each Contributor should specifically review his/her statement on file and notify the Academy of any changes to his/her financial disclosures. These requirements apply to relationships that are in place at the time of or were in place 24 months preceding the presentation, publication submission, or nomination to a leadership position. Any financial relationship that may constitute a conflict of interest will be mitigated prior to the delivery of the activity.

Financial Relationship Disclosure

For purposes of this disclosure, a known financial relationship is defined as any financial gain or expectancy of financial gain brought to the Contributor by:

Direct or indirect compensation;
Ownership of stock in the producing company;
Stock options and/or warrants in the producing company, even if they have not been exercised or they are not currently exercisable;
Financial support or funding to the investigator, including research support from government agencies (e.g., NIH), device manufacturers, and\or pharmaceutical companies.

Description of Financial Interests

Code	Description
C	Consultant/Advisor Consultant fee, paid advisory boards, or fees for attending a meeting.
E	Employee Hired to work for compensation or received a W2 from a company.
L	Lecture Fees/Speakers Bureau Lecture fees or honoraria, travel fees or reimbursements when speaking at the invitation of a commercial company.
P	Patents/Royalty Beneficiary of patents and/or royalties for intellectual property.
S	Grant Support Grant support or other financial support from all sources, including research support from government agencies (e.g., NIH), foundations, device manufacturers, and\or pharmaceutical companies. Research funding should be disclosed by the principal or named investigator even if your institution receives the grant and manages the funds.
EE	Employee, Executive Role Hired to work in an executive role for compensation or received a W2 from a company.
EO	Owner of Company Ownership or controlling interest in a company, other than stock.
SO	Stock Options Stock options in a private or public company.
PS	Equity/Stock Holder - Private Corp (not listed on the stock exchange) Equity ownership or stock in privately owned firms, excluding mutual funds.
US	Equity/Stock Holder - Public Corp (listed on the stock exchange) Equity ownership or stock in publicly traded firms, excluding mutual funds.
I	Independent Contractor Contracted work, including contracted research

Disclosure list contains individual’s relevant disclosures with ineligible companies. All relevant financial relationships have been mitigated.

Secretary for Annual Meeting

Name	Disclosure
Bennie H. Jeng, MD	GlaxoSmithKline: C; Kiora: US

Annual Meeting Program Committee

The Annual Meeting Program Committee is responsible for the Academy's annual meeting Scientific Program, including Instruction Courses, Symposia, the Spotlight on Cataract, Ask the Experts, Scientific Papers/Posters and Videos. Each subcommittee has five - ten reviewers who grade the instruction courses and paper/poster abstracts as well as three subcommittee members who review the grades, then select the courses and abstracts for presentation.

Associate Secretary for the Annual Meeting Program	Disclosure
Sharon D. Solomon, MD	NONE
Annual Meeting Program Committee
Surendra Basti, MBBS	Johnson & Johnson Vision: C
Jessica B. Ciralsky, MD	NONE
Paula Anne Newman-Casey, MD	National Institute of Biomedical Imaging and Bioengineering: S
Julie Falardeau, MD	Medpace: S
Jonathan W. Kim, MD	NONE
Martha P. Schatz, MD	NONE
Elizabeth Yeu, MD	Abbvie: C; AcuFocus, Inc.: C; Advanced Vision Group: C; Alcon Laboratories, Inc.: C,L; Aldeyra Therapeutics Inc: C; Allergan, Inc.: C,L; Aurion: C; Avellino Labs: C; Bausch + Lomb: C; Bio-Tissue, Inc.: C,L; BlephEX, LLC: C; Bruder Healthcare Company: C; BVI: C; Carl Zeiss Meditec: C,L; Centricity: C; CorneaGen: C; Dompe: C; Elios: C; Expert Opinion: C; Eyenovia: C; Foresight: C; Glaukos Corporation: C,L; Guidepoint: C; Iveric Bio: C; Johnson & Johnson Vision: C,L; Kala Pharmaceuticals, Inc.: C; LayerBio: C; LENSAR: C; Melt: C; Merck & Co., Inc.: C; New World Medical, Inc.: C; Novartis Pharma AG: C; Ocular Science: C; OCuSOFT, Inc.: C; Samsara: C; Science Based Health: C; Sight Sciences, Inc.: C; STAAR Surgical: C; Surface: C; Tarsus Pharmaceuticals: C,S; THEA: C; Visus Therapeutics Inc: C
Sunir J. Garg, MD, FACS	Allergan, Inc.: C; Apellis Pharmaceuticals, Inc.: S; Bausch + Lomb: C; Boehringer Ingelheim: C,S; Coherus: C; Johnson & Johnson: C; Kodiak: S; Merck Manual: C; NGM Bio: S; Regeneron Pharmaceuticals, Inc.: S

Subcommittee for: Cataract

Chair	Disclosure
Surendra Basti, MBBS	Johnson & Johnson Vision: C
Subcommittee Members
Brandon Ayres, MD	Alcon Laboratories, Inc.: C,L; Allergan, Inc.: C,L; Bausch + Lomb: L; Carl Zeiss Inc: C; CorneaGen: C; Dompe: C,L; Glaukos Corporation: C; New World Medical Inc: C; Novartis, Alcon Pharmaceuticals: C; Sun Ophthalmics: C,L
Sathish Srinivasan, MBBS	AcuFocus, Inc.: C; Alcon Laboratories, Inc.: C; Carl Zeiss Meditec: C; DORC International, bv/Dutch Ophthalmic, USA: C; Medicontur International SA: C; Scope Ophthalmics: C; THEA: L
Subcommittee Reviewers
Jeremy Z. Kieval, MD	Johnson & Johnson: C,L; Kala Pharmaceuticals, Inc.: C,L; LENSAR: C; Novartis Pharma AG: C; Ocular Therapeutix: C; SeaGen: C; Tarsus Pharmaceuticals: C; Versea Ophthalmics: C; Visus Therapeutics Inc: C
Sumitra S. Khandelwal, MD	Alcon Laboratories, Inc.: C; Bausch + Lomb: C; Carl Zeiss Meditec: C; Dompe: C; Kala Pharmaceuticals, Inc.: C; Ocular Therapeutix: C
Anjali Tannan, MD	NONE
Kourtney A. Houser, MD	Alcon Laboratories, Inc.: S; Allergan, Inc.: C; Avellino Labs: C; Bausch + Lomb: C,L; Carl Zeiss Meditec: C; Novartis, Alcon Pharmaceuticals: C; orasis: C; RVL Pharmaceuticals, Inc.: C; Sight Sciences, Inc.: C; Tarsus Pharmaceuticals: C
Kamran M. Riaz, MD	Ambrx: C; Bausch + Lomb: L; CorneaGen: L; Exelexis: C; ImmunoGen: C; PrecisionLens: L

Subcommittee for: Cornea, External Disease

Chair	Disclosure
Jessica B. Ciralsky, MD	NONE
Subcommittee Members
Elmer Y. Tu, MD	Daiichi Sankyo: C; Dompe: C; GlaxoSmithKline: C; Oyster Point Pharma: C; Profounda: C; Santen, Inc.: C; Seagen: C; Sifi Pharma: C
Anat Galor, MD	Allergan, Inc.: C; Astrozenica: C; Dompe: C; Eyecool: C; Novaliq GmbH: C; Novartis Pharma AG: C; Oculis: C; Oyster Point Pharma: C; Shire: C; Tarsus Pharmaceuticals: C
Subcommittee Reviewers
Vatinee Y. Bunya, MD	NONE
Vishal Jhanji, MD, FRCOphth	NONE
Christina R. Prescott, MD	Johnson & Johnson Vision: C
Peter B. Veldman, MD	WL Gore: C
Christopher S. Sales, MD	Network Medical Review: P

Subcommittee for: Glaucoma

Chair	Disclosure
Paula Anne Newman-Casey, MD	National Institute of Biomedical Imaging and Bioengineering: S
Subcommittee Members
John T. Lind, MD	Abbvie: S; Heru: S; Nicox: S
Jenny Chen, MD	NONE
Subcommittee Reviewers
Luis E. Vazquez, MD, PhD	New World Medical, Inc.: L
Ahmara G. Ross, MD	Gene Therapy for Ocular Disorders (Patent Number 16/607,834, 2019): P; Gyroscope Therapeutics: C,I; Noveome: C,P,S
Natasha Nayak Kolomeyer, MD	Abbvie: C,S; Aerie Pharmaceuticals, Inc.: S; Allergan, Inc.: C,S; Diopsys, Inc.: S; Equinox: S; Glaukos Corporation: S; Guardion Health Sciences: S; Nicox: S; Olleyes Inc: S; Santen, Inc.: S
Brian C. Stagg, MD	NONE
Catherine Q. Sun, MD	All May See Foundation: S

Subcommittee for: Neuro-Ophthalmology, Electronic Health Records/Information Technology, Ethics, General Medical, Global Ophthalmology, Medical Education, Ophthalmic History, Vision Rehabilitation and Wellness

Chair	Disclosure
Julie Falardeau, MD	Medpace: S
Subcommittee Members
John J. Chen, MD, PhD	Horizon Therapeutics Plc: C; UCB: C
Nagham Al-Zubidi, MD	NONE
Subcommittee Reviewers
Madhura A. Tamhankar, MD	Horizon Therapeutics Plc: C, L; UpToDate Inc.: P; Viridian Therapeutics: C
Reid A. Longmuir, MD	Astra Zeneca/Daiichi Sankyo: C
Ore-Ofeoluwatomi O. Adesina, MD	NONE
Amanda D. Henderson, MD	Horizon Therapeutics Plc: C
Shauna E. Berry, DO	NONE

Subcommittee for: Ocular Pathology, Oncology and Oculoplastics, Orbit

Chair	Disclosure
Jonathan W. Kim, MD	NONE
Subcommittee Members
Steven M. Couch, MD	Horizon Therapeutics Plc: S; Sling Therapeutics: S; Viridian Therapeutics: S
Michael K. Yoon, MD	Horizon Therapeutics Plc: US
Subcommittee Reviewers
Kenya M. Williams, MD	BioTissue: L; Horizon Therapeutics Plc: L
Catherine J. Hwang, MD	NONE
Daniel B. Rootman, MD, MSc	Cellularity: C; Horizon Therapeutics Plc: C
Anne Barmettler, MD	NONE
Sandy X. Zhang-Nunes, MD	Bruder Healthcare Company: C; Horizon Therapeutics Plc: C; Sciton: C; Tarsus Pharmaceuticals: C

Subcommittee for: Pediatric Ophthalmology, Strabismus

Chair	Disclosure
Martha P. Schatz, MD	NONE
Subcommittee Members
Federico G. Velez, MD	Novartis: S
Stacy L. Pineles, MD	Asteroid 3D: S; Fitz frames: C; Horizon Surgical: PS
Subcommittee Reviewers
Tina Rutar, MD	Sydnexis: S,SO,C
Ujwala Saboo, MD	NONE
Judith E. Gurland, MD	NONE
Mitchell B. Strominger, MD	Horizon Therapeutics Plc: L

Subcommittee for: Refractive Surgery and Optics, Refraction, Contact Lenses

Chair	Disclosure
Elizabeth Yeu, MD	Abbvie: C; AcuFocus, Inc.: C; Advanced Vision Group: C; Alcon Laboratories, Inc.: C,L; Aldeyra Therapeutics Inc: C; Allergan, Inc.: C,L; Aurion: C; Avellino Labs: C; Bausch + Lomb: C; Bio-Tissue, Inc.: C,L; BlephEX, LLC: C; Bruder Healthcare Company: C; BVI: C; Carl Zeiss Meditec: C,L; Centricity: C; CorneaGen: C; Dompe: C; Elios: C; Expert Opinion: C; Eyenovia: C; Foresight: C; Glaukos Corporation: C,L; Guidepoint: C; Iveric Bio: C; Johnson & Johnson Vision: C,L; Kala Pharmaceuticals, Inc.: C; LayerBio: C; LENSAR: C; Melt: C; Merck & Co., Inc.: C; New World Medical, Inc.: C; Novartis Pharma AG: C; Ocular Science: C; OCuSOFT, Inc.: C; Samsara: C; Science Based Health: C; Sight Sciences, Inc.: C; STAAR Surgical: C; Surface: C; Tarsus Pharmaceuticals: C,S; THEA: C; Visus Therapeutics Inc: C
Subcommittee Members
Kathryn Masselam Hatch, MD	Alcon Laboratories, Inc.: C; Alderya Therapeutics, Inc.: C; Carl Zeiss Meditec: C; cxlo: C; Glaukos Corporation: C,US; Johnson & Johnson Vision: C; Kala Pharmaceuticals, Inc.: C; MYZE: C,PS; tilleron: EO
Edward E. Manche, MD	Alcon Laboratories, Inc.: S; Allergan, Inc.: S; Avedro, Inc.: C,S; Best Doctors, Inc.: C; Carl Zeiss Inc: C,S; Glaukos Corporation: S; Johnson & Johnson Vision: C,S; KKR: C; Novartis Pharma AG: S; Placid0: PS,SO; Presbia: S; RxSight Inc: US; VacuSite: P,PS
Subcommittee Reviewers
Denise M. Visco, MD	Bausch + Lomb: C; Carl Zeiss Inc: C,L; Cassini Technologies: C; LENSAR: C,L; Oyster Point Pharma: C; Rayner Intraocular Lenses Ltd: C; Sun Pharmaceuticals: C,L
Gregory D. Parkhurst, MD	STAAR Surgical: C,L
Dagny C. Zhu, MD	Alchemy Vision: C; Alcon Laboratories, Inc.: C,S; Allergan, Inc.: C,L; Bausch + Lomb: C,L; Beyeonics Surgical, Ltd.: C; Bruder Healthcare Company: C; Entelexo: C; epion therapeutics: C; eyenovia: C; eyesafe: C; Johnson & Johnson Vision: C; Kala Pharmaceuticals, Inc.: C; LENSAR: C; neurotech: C; Ocuphire: C; RadiusXR: C,SO; Santen, Inc.: L; Sight Sciences, Inc.: C; STAAR Surgical: C; Tarsus Pharmaceuticals: C,L; Trukera Medical: C; Visus : C
Caroline C. Watson, MD	Abbvie: C; Alcon Laboratories, Inc.: C,L; Bausch + Lomb: C; Beyeonics Surgical, Ltd.: C; Carl Zeiss Meditec: C,L; Dompe: C,L; Johnson & Johnson Vision: C,L; Lumenis Vision: C,L; MicroSurgical Technology: C; RxSight Inc: C; Tarsus Pharmaceuticals: C,L; Visus Therapeutics: C
Brian M. Shafer, MD	Alcon Laboratories, Inc.: C; Allergan, Inc.: L

Subcommittee for: Retina, Vitreous and Uveitis, Intraocular Inflammation

Chair	Disclosure
Sunir J. Garg, MD, FACS	Allergan, Inc.: C; Apellis Pharmaceuticals, Inc.: S; Bausch + Lomb: C; Boehringer Ingelheim: C,S; Coherus: C; Johnson & Johnson: C; Kodiak: S; Merck Manual: C; NGM Bio: S; Regeneron Pharmaceuticals, Inc.: S
Subcommittee Members
Yannis Mantas Paulus, MD	IRIDEX: C; MediBeacon: C; PhotoSonoX LLC: EO,PS
Anita Agarwal, MD	NONE
Subcommittee Reviewers
Jennifer E. Thorne, MD, PhD	AbbVie: C; Canfield Scientific, Inc: C; Clearview Royal Lessee LLC dba Royal St Charles: C; Gilead Sciences: C; Roche Diagnostics: C; Tarsier Pharma: C,SO; UptoDate: C
Jaclyn L. Kovach, MD	Iveric Bio: C; Regeneron Pharmaceuticals, Inc.: L
Bryn M. Burkholder, MD	NONE
John A. Gonzales, MD	NONE
Christopher J. Brady, MD	Merck & Co., Inc.: I
Jessica D. Randolph, MD	Astellas: C; GENENTECH: C
Jay K. Chhablani, MBBS	Abbvie: L; AcuViz: SO; Allergan, Inc.: L; Erasca: C; Novartis Pharma AG: C; Ocular Therapeutix: US; Salutaris: C
Vaidehi Shradha Dedania, MD	Character Bio: C; EyePoint: C; GENENTECH: C; Iveric Bio: C; Spark Therapeutics, Inc.: C
Alice Yang Zhang, MD	NONE
Mark Philip Breazzano, MD	NONE

Special Projects Committee

The Special Projects Committee is responsible for developing programming and formats that cross subspecialties, as well as complement those that are submitted by members or societies.

Associate Secretary	Disclosure
Carolyn K. Pan, MD	NONE
Committee Members
Laura B. Enyedi, MD	Cooper Vision: C; Novartis: C; Ocular Therapeutix: S; Sophia Pharma: L
John J. DeStafeno, MD	Sun Ophthalmics: L
Collin M. McClelland, MD	NONE
Amina I. Malik, MD	Horizon Therapeutics Plc: C
Beeran B. Meghpara, MD	Allergan, Inc.: C,L; Biotissue: C; Carl Zeiss Meditec: C; Centricity: C; CorneaGen: C; Dompe: L,C; Glaukos Corporation: C; Johnson & Johnson Vision: C; Kala Pharmaceuticals, Inc.: L,C; Oculus, Inc.: C; Orasis: C; Santen, Inc.: C,L; Sight Sciences, Inc.: C; Sun Ophthalmics: C,L; Tarsus Pharmaceuticals: C; THEA: C; W.L Gore & Associates: C
Kateki Vinod, MD	NONE

Skills Transfer Advisory Committee

The Skills Transfer Advisory Committee is responsible for selecting the Skills Transfer courses and labs.

Associate Secretary	Disclosure
Michael L. Savitt, MD	NONE
Advisory Members
Brock K. Bakewell, MD	NONE
Keye L. Wong, MD	NONE
Brian A. Francis, MD	Aerie Pharmaceuticals, Inc.: C,L; Alcon Laboratories, Inc.: C,S; Allergan, Inc.: C,S; Beaver-Visitec International, Inc.: C; Greybug: C; IRIDEX: C; iSTAR Medical: C; MicroSurgical Technology: C; New World Medical, Inc.: S; THEA: C
Parag A. Majmudar, MD	Alcon Laboratories, Inc.: C; Bausch + Lomb: C; Carl Zeiss Meditec: C; Dompe: C; Kala Pharmaceuticals, Inc.: C; Novaliq GmbH: C; Sun Pharma: C; Zhaoke Ophthalmology: C
Cat Burkat, MD, FACS	NONE
Clara C. Chan, MD	Abbvie: C,L; Aequus Pharmaceuticals: C; Allergan, Inc.: C,L,S; Carl Zeiss Meditec: C; Daichii: C; Dompe: C; Johnson & Johnson Vision: C,US; Labtician Ophthalmics, Inc.: C,L; Novartis Pharma AG: C,S; Pfizer, Inc.: US; Santen, Inc.: C,L; Sun Ophthalmics: C; THEA: C,L

Subspecialty Day Advisory Committee

Associate Secretary	Disclosure
R. Michael Siatkowski, MD	NONE
Advisory Members
Jody R. Piltz, MD	Aerie Pharmaceuticals, Inc.: C,L; Alcon Laboratories, Inc.: C,L; Nanoscope therapeutics : C
Jennifer Irene Lim, MD	Adverum Biotechnologies: S; Alderya Therapeutics, Inc.: S; Allergan, Inc.: C; Aura Biosciences, Inc.: C; Chengdu Kanghong: S; Cognition Therapeutics: C; Eyenuk, Inc.: C; GENENTECH: C,S,L; Greybug: S; Iveric Bio: C; JAMA Network: C; Janssen Pharmaceuticals, Inc.: S; Luxa: C; NGM: S; Novartis Pharma AG: C; Opthea: C; Quark Pharmaceuticals: C; Regeneron Pharmaceuticals, Inc.: C,S; Santen, Inc.: C; Spring vision: S; Stealth Biotherapeutics: S; Taylor & Francis (CRC Press): P; Unity: C; Viridian: C
Sonia H. Yoo, MD	Carl Zeiss Meditec: C; Dermavant: C; Oyster Point Pharma: C
Shahzad I. Mian, MD	Andover Eye Associates: S; Kowa American Corporation: S; Novartis: S; VisionCare, Inc.: S
Julie Falardeau, MD	Medpace: S

Subspecialty Day

Cornea

Program Directors	Disclosure
Sonal S. Tuli MD	Kowa Pharmaceutical Co. Ltd.: S; Recordati Rare Diseases: S
Christina R. Prescott, MD, PhD	Johnson & Johnson Vision: C
Christopher S. Sales, MD	Network Medical Review: P
Program Planning Group
Sonal S. Tuli MD	Kowa Pharmaceutical Co. Ltd.: S; Recordati Rare Diseases: S
Christina R. Prescott, MD, PhD	Johnson & Johnson Vision: C
Christopher S. Sales, MD	Network Medical Review: P

Glaucoma

Program Directors	Disclosure
Teresa C. Chen, MD	Alcon Laboratories, Inc.: S; Harvard Foundation Grant (Fidelity Charitable Fund): S
Steven L. Mansberger, MD, MPH	Abbvie: S, IQVIA: S, Nicox: C, ONL Therapeutics: C, Perfuse: C, THEA: C,S
Program Planning Group
Teresa C. Chen, MD	Alcon Laboratories, Inc.: S, Harvard Foundation Grant (Fidelity Charitable Fund): S
Steven L. Mansberger, MD, MPH	Abbvie: S, IQVIA: S, Nicox: C, ONL Therapeutics: C, Perfuse: C, THEA: C,S
Robert T. Chang, MD	1800 Contacts: C, Alcon Laboratories, Inc.: C, Belkin laser: C, GENENTECH: C,S, Ocular Therapeutix: C, Optomed Corporation: C, Sight Sciences, Inc.: C, Smartlens: C, Verana Health: C, XP health: C
Anna T. Do, MD	Abbvie: L
Christopher A. Girkin, MD, MSPH	Amydis: SO, Heidelberg Engineering: C, S, IRIDEX: C, , Topcon Medical Systems Inc.: C, S
Leon W Herndon Jr., MD	Aerie Pharmaceuticals, Inc.: C, Alcon Laboratories, Inc.: C, Allergan, Inc: C, L, Elios: C, Equinox: C, GENENTECH: C, Glaukos Corporation: C, L, Graybug: C, New World Medical, Inc.: C, L, Ocular Therapeutix: C, S, Sight Sciences, Inc.: C
Robert J. Noecker, MD, MBA	Abbvie: C, L, Alcon Laboratories, Inc.: C, L, Bausch + Lomb: C, L, Beaver-Visitec International, Inc.: C, Glaukos Corporation: C, S, IRIDEX: C, L, New World Medical Inc.: L, C, Ocular Therapeutix: C, SO, Santen, Inc.: C, Sight Sciences, Inc.: C, SO, L, THEA: C
Mary Qiu, MD	NONE
Manjool M. Shah, MD	Alcon Laboratories, Inc.: C, Allergan/Abbvie: C, Elios: C, Glaukos Corporation: C, Katena Products, Inc.: C, Nova Eye Medical: C, ONL Therapeutics: C
Ramya N. Swamy, MD, MPH	NONE
Richard Dwight Ten Hulzen, MD	NONE
Luis E. Vazquez, MD, PhD	New World Medical, Inc.: L

Oculofacial Plastic Surgery

Program Directors	Disclosure
Cat Burkat MD FACS	NONE
Steven M. Couch, MD	Horizon Therapeutics Plc: S; Sling Therapeutics: S; Viridian Therapeutics: S
Program Planning Group
Cat Burkat MD FACS	NONE
Steven M. Couch, MD	Horizon Therapeutics Plc: S; Sling Therapeutics: S; Viridian Therapeutics: S

Neuro-Ophthalmology

Program Directors	Disclosure
Peter A. Quiros, MD	Invex Pharmaceuticals: C, Research to Prevent Blindness: S
Madhura A. Tamhankar, MD	Horizon Therapeutics Plc: C, L, UpToDate Inc.: P, Viridian Therapeutics: C
Program Planning Group
Peter A. Quiros, MD	Invex Pharmaceuticals: C, Research to Prevent Blindness: S
Madhura A. Tamhankar, MD	Horizon Therapeutics Plc: C, L, UpToDate Inc.: P, Viridian Therapeutics: C
Eric L. Berman, MD	NONE
Chantal Boisvert, MD	OVID Therapeutics: S, Viridian Therapeutics: S
John J. Chen, MD, PhD	Horizon Therapeutics Plc: C, UCB: C
Michael Dattilo, MD	NONE
Kathleen B. Digre, MD	ELSEVIER: P, part owner on a patent pending thin-filmed technology; no company involved: P, Springer: P
Valerie I. Elmalem, MD	Horizon Therapeutics Plc: C,L
Courtney E. Francis, MD	NONE
Kimberly K. Gokoffski, MD	NONE
Lynn K. Gordon, MD PhD	Vedere: C
Guy V. Jirawuthiworavong, MD	NONE
Sachin Kedar, MD	NONE
Andrew G. Lee, MD	Astrazeneca: C, Bristol Mayers Squibb: C, Horizon Therapeutics Plc: C,L
Collin M. McClelland, MD	NONE
Andrew Melson, MD	Horizon Therapeutics Plc: C
Jason H. Peragallo, MD	NONE

Refractive Surgery

Program Directors	Disclosure
Jodhbir S. Mehta, MBBS	ACEVision: SO; BMRC (Singapore): S; Carl Zeiss Inc: L; CordLife: P; Lecia Microsystems Inc.: L; Moria: L; NMRC (Singapore): S; Network Medical Review: P; Santen Inc: L; Trefoil Therapeutics: SO; Ziemer Ophthalmics AG: L
Nicole R. Fram, MD	Alcon Laboratories, Inc.: C; Aurion Biotechnology: C; Avellino Labs: C; Beaver-Visitec International, Inc.: L; Carl Zeiss Meditec: C, L, S; CorneaGen: C, L, S, O; Glaukos Corporation: L; Johnson & Johnson Vision: L, C; LENSAR: C; Ocular Science: SO, C; Ocular Therapeutix: S; Orasis Pharmaceuticals Inc: C, SO; RxSight Inc: L, C; Vital Tears: L
Program Planning Group
Renato Ambrosio, Jr., MD	Alcon Laboratories, Inc.: C; Allergan: L; Carl Zeiss, Inc.: L; Essilor Instruments: L; Genom: C,L; Mediphacos: L; Oculus, Inc.: C
Deepinder K. Dhaliwal, MD	Allergan, Inc: C, Glaukos Corporation: S, Haag-Streit Group: C, Johnson & Johnson Vision: C, Kowa American Corporation: S, LENZ Therapeutics: C, Novartis: C, S, Noveome: S, Oyster Point Pharma: C, STAAR Surgical: C, TearSolutions: C, Trefoil Therapeutics: C
Nicole Fram, MD	Alcon Laboratories, Inc.: C, Aurion Biotechnology: C, Avellino Labs: C, Beaver-Visitec International, Inc.: L, Carl Zeiss Meditec: C, L, S, CorneaGen: C, L, S, O, Glaukos Corporation: L, Johnson & Johnson Vision: L, C, LENSAR: C, Ocular Science: SO, C, Ocular Therapeutix: S, Orasis Pharmaceuticals Inc: C, SO, RxSight Inc: L, C, Vital Tears: L
Jodhbir S. Mehta MBBS	ACEVision: SO, BMRC (Singapore): S, Carl Zeiss Inc: L, CordLife: P, Lecia Microsystems Inc.: L, Moria: L, Network Medical Review: P, NMRC (Singapore): S, Santen Inc: L, Trefoil Therapeutics: SO, Ziemer Ophthalmics AG: L
J. Bradley Randleman, MD	NONE
Sonia H. Yoo MD	Carl Zeiss Meditec: C, Dermavant: C, Oyster Point Pharma: C

Retina

Program Directors	Disclosure
Timothy G. Murray, MD, MBA	Alcon Laboratories, Inc.: C; U.S. Food and Drug Administration: C
Barbara Ann Blodi, MD	NONE
Program Planning Group
Timothy G. Murray, MD, MBA	Alcon Laboratories, Inc.: C; U.S. Food and Drug Administration: C
Barbara Ann Blodi, MD	NONE
Sophie J. Bakri, MD	Abbvie: C, Adverum: C, Alcon Pharmaceuticals Ltd: C, Alimera Sciences, Inc.: C, Allergan, Inc.: C, Apellis Pharmaceuticals, Inc.: C, Carl Zeiss Meditec: C, EyePoint Pharmaceuticals: C, GENENTECH: C, Ilumen: C, Iveric Bio: C, Kala Pharmaceuticals, Inc.: C, Novartis Pharmaceuticals: C, Outlook Therapeutics: C, Pixium Vision: C, Regeneron Pharmaceuticals, Inc.: C, REGENXBIO: C, S, ReVana: SO, Roche Pharmaceuticals: C, VoxelCloud: SO
Diana V Do, MD	Alimera Sciences, Inc.: C, Apellis Pharmaceuticals, Inc.: C, Belite Bio: C, Boehringer Ingelheim: C, S, GENENTECH: C, Iveric Bio: C, Kodiak Sciences Inc.: C, US, Kriya Therapeutics: C, Regeneron Pharmaceuticals, Inc.: C, S

Ocular Oncology and Pathology

Program Directors	Disclosure
Claudia Maria Prospero Ponce, MD	NONE
Miguel A. Materin, MD	Astra Zeneca: C; Carl Zeiss Meditec: L; Castle Biosciences, Inc.: C; Ideaya Biosciences: C
Program Planning Group
Miguel A. Materin MD	Astra Zeneca: C; Carl Zeiss Meditec: L; Castle Biosciences, Inc.: C; Ideaya Biosciences: C
Claudia Maria Prospero Ponce, MD	NONE
Matthew W. Wilson MD	Immunocore: C

AAOE Content Committee

The AAOE Annual Meeting Program Committee is responsible for selecting the AAOE Instruction Courses, Coding Sessions and the Practice Management Master Classes.

Chair	Disclosure
Bansari Mehta, MHA	NONE
Committee Members
Natalie M. Loyacano, COMT, OCSR	NONE
Christine M. McDonald	NONE
Sondra Hoffman, COE, CPC, CMPE	Hoffman Consulting Group: EE
Rahul Bhola, MD, MBA	NONE
Joanne Mansour, OCSR	NONE
Savory A. Turman, COMT	NONE
Tori A. Elkins, COE, COT, MBA	NONE
Bansari Mehta, MHA	NONE
Heather Modjesky, COE	NONE
Alicia Reynolds	NONE

Academy Staff

Name	Disclosure
Debra Rosencrance	NONE
Melanie Rafaty	NONE
Sangeeta Fernandes	NONE
Ann L'Estrange	NONE
Susan Oslar	NONE
Elizabeth Washburn	NONE
Licia Wells	NONE
Julia Fennell	NONE
Mecca Boutte	NONE
Virginia Young	NONE

Most Commented

Loading, please wait...

There are no comments available.

Most Viewed

Loading, please wait...

Most Viewed content is not available.

All content on the Academy’s website is protected by copyright law and the Terms of Service. This content may not be reproduced, copied, or put into any artificial intelligence program, including large language and generative AI models, without permission from the Academy.